April 30, 2013
by John Paul Regan
JURIST Guest Columnist Bruce Abramson of Rimon PC argues that in the absence of sufficient evidence, public policy favors the patentability of genetic tools...The conventional shorthand for the Association for Molecular Pathology v. Myriad, Inc. case, argued before the Supreme Court on April 15, ...[read more]
April 15, 2013
by Michael Haggerson
The US Supreme Court heard oral arguments Monday in Association for Molecular Pathology v. Myriad Genetics, Inc., which deals with the issue of whether human genes are patentable. Myriad Genetics patented two genes, BRCA1 and BRCA2, which are isolated genes?different from native genes becaus... ...[read more]
December 1, 2012
by Jaimie Cremeans
US Supreme Court on Friday granted certiorari in Association for Molecular Pathology v. Myriad Genetics, Inc., which deals with the issue of whether human genes are patentable. Myriad Genetics patented two genes, BRCA1 and BRCA2, which are isolated genes—different from native genes because th... ...[read more]
September 26, 2012
by Jerry Votava
The American Civil Liberties Union (ACLU) and the Public Patent Foundation (PUBPAT) on Tuesday asked the US Supreme Court to review the validity of patents on two genes associated with breast and ovarian cancers owned by a Utah company, Myriad Genetics. The patents at issue concern BRCA1 and ...[read more]
August 17, 2012
by Dan Taglioli
The US Court of Appeals for the Federal Circuit (CAFC) on Thursday ruled for the second time in Association for Molecular Pathology v. US Patent and Trademark Office (AMP) that a Utah company does have valid patents on two genes associated with breast and ovarian cancers. AMP concerned Myriad ...[read more]
July 23, 2012
by Dan Taglioli
The US Court of Appeals for the Federal Circuit on Friday heard arguments in Association for Molecular Pathology v. US Patent and Trademark Office (AMP), an ongoing case that challenged a Utah company's patent on two genes associated with breast and ovarian cancers. The three-judge panel is ...[read more]
June 17, 2012
by Jaimie Cremeans
The American Civil Liberties Union (ACLU) and the Public Patent Foundation (PUBPAT) filed a brief with the US Court of Appeals for the Federal Circuit on Friday in Association for Molecular Pathology v. US Patent and Trademark Office, an ongoing case challenging a Utah company's patent on genes ...[read more]
July 31, 2011
by Andrea Bottorff
The Court of Appeals for the Federal Circuit on Friday ruled 2-1 that patents held on two genes linked to hereditary ovarian and breast cancer are valid. The American Civil Liberties Union (ACLU) and the Public Patent Foundation (PUBPAT) originally filed the suit on behalf of patients and ...[read more]
October 30, 2010
by Daniel Makosky
The Department of Justice (DOJ) on Friday filed an amicus curiae brief in the US Court of Appeals for the Federal Circuit revising the government's stance on patenting isolated genetic material, including human genes. The position represents a significant departure from established policy, which ...[read more]
March 30, 2010
by Hillary Stemple
A judge for the US District Court for the Southern District of New York ruled Monday that patents held on two genes linked to hereditary ovarian and breast cancer are invalid. The ruling was in response to a suit filed by the American Civil Liberties Union (ACLU) and the Public Patent Foundation ( ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.